

CANADIAN CANCER TRIALS GROUP
BRAIN
DISEASE SITE COMMITTEE MEETING AGENDA
OPEN SESSIONS

Venue: CARLYLE

Date: Saturday, April 29th 2017

Time: 9:00 a.m. – 12:00 p.m.

Chair: Dr. Warren Mason

9:00 am **Welcome and Introductions**

9:05 am Summary of results from the CCSRI Grant review **W. Mason**

Brief Updates on Completed Studies & Studies Closed to Accrual

9:15 am **CE.6:** A Randomized Phase III Study of Temozolomide a Short- Course Radiation versus Short-Course Radiation Alone in the Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients-manuscript published
.
J. Perry & N. Laperriere

CEC.1 (EORTC 26053_22054): Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19Q Deleted Anaplastic Glioma.
The CATNON Intergroup Trial-manuscript status **W. Mason & C. O'Callaghan**

CE.5 (EORTC 22033-26033): Primary Chemotherapy with Temozolomide vs Radiotherapy in Patients with Low-Grade Gliomas After Stratification for Genetic 1P Loss: A Phase III Study – manuscript published **W. Mason**

Actively Accruing Trials

9:30 am **CEC.6 (NCCTG N0577):** Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma
C. O'Callaghan

9:40 am **IND.222:** A phase I/II trial of AZD2014 with temozolomide in patients with GBM at first progression **W.Mason**

Newly Approved/Opened CCTG Trials

- 9:50 am **CEC.5 (ALLIANCE 221208):** Randomized Phase II Study: Corticosteroids + Bevacizumab vs Corticosteroids + Placebo (BeSt) for Radionecrosis after Radiosurgery for Brain Metastases **C. Chung**
- 10:00 am **CEC.3 (NCCTG N107C) *closed*:** A phase III trial of post-surgical stereotactic radiosurgery compared with whole brain radiotherapy (WBRT) for resected metastatic brain disease **D. Roberge**
- CE.7:** A Phase III Trial of Stereotactic Radiosurgery compared with Whole Brain Radiotherapy (WBRT) for 5-15 Brain Metastases **D. Roberge**
- 10:15-10:30 am Coffee Break

Miscellaneous

- 10:30 am Stand up to Cancer Canada Brain Tumour Research Grant: Status Report **P. Dirks**
- 10:55am Potential future trial: A phase III trial of the pan-proteasome inhibitor Marizomib with Radiotherapy and Temozolomide for newly-diagnosed GBM
- Marizomib: Background, rational for evaluation in GBM, pre-clinical data, overview of completed and ongoing phase I/II trials of agent in recurrent and newly-diagnosed GBM **M. Trikha**
 - Proposed EORTC phase III trial design in newly-diagnosed GBM **W.Mason**
- 11:20 am Normograms for predicting survival of elderly patients with glioblastoma: A prognostic factors analysis based on CE.6 **F. Moraes**
- 11:45 am Report from IND Committee **M. Pitz**
- 12:00 pm **Closing Remarks**